found that MDSC inhibition using anti‐Ly6G antibody or the LXR agonist GW3965, combined with TAM depletion via anti‐CSF1R antibody, improved anti‐PD‐1 efficacy, extending survival and reducing tumor progression. The gene discussed is CSF1R; the disease is neoplasm.